Endogenous insulin testing measures insulin naturally secreted by pancreatic beta cells and distinguishes it from exogenous (administered) insulin through companion biomarkers such as C-peptide and proinsulin. It is essential for the differential diagnosis of hypoglycemia, assessment of residual beta-cell function, anti-doping surveillance, and pharmaceutical research. This article reviews the physiological basis, sample requirements, analytical methods, quality standards, and practical applications of endogenous insulin detection.
Technical Overview
Endogenous insulin testing refers to the laboratory measurement of insulin produced by the pancreatic beta cells, together with the co-secreted markers C-peptide and proinsulin, in order to quantify endogenous beta-cell secretion and to differentiate it from insulin introduced from pharmaceutical preparations. Because exogenous insulin and insulin analogues suppress endogenous secretion through feedback regulation while contributing no C-peptide, the combined interpretation of insulin, C-peptide, and proinsulin provides a powerful diagnostic framework used in clinical endocrinology, doping control, and drug development.
Physiology of Endogenous Insulin Secretion
Insulin is a 51-amino-acid peptide hormone of approximately 5.8 kDa, composed of an A-chain and a B-chain joined by two disulfide bonds. It is synthesized as preproinsulin, processed to proinsulin, and cleaved within secretory granules into insulin and C-peptide, which are released into the portal circulation in equimolar amounts. Insulin has a short plasma half-life of roughly 4 to 6 minutes owing to rapid hepatic clearance, whereas C-peptide has a half-life of approximately 20 to 35 minutes and undergoes minimal hepatic extraction, making it a more stable and cumulative reflection of endogenous secretion.
Endogenous Versus Exogenous Insulin
Pharmaceutical insulin products include regular human insulin and engineered analogues such as lispro, aspart, glulisine, glargine, detemir, and degludec. These preparations contain no C-peptide. Consequently, hypoglycemia accompanied by elevated insulin but suppressed C-peptide points to exogenous insulin administration, whereas elevation of insulin, C-peptide, and often proinsulin indicates endogenous hyperinsulinism, such as insulinoma or exposure to insulin secretagogues. Because commercial immunoassays differ in their cross-reactivity with analogues, documented method performance is a critical element of any testing strategy.
Key Biomarkers
- Insulin: the primary effector hormone, reported in µIU/mL or pmol/L (1 µIU/mL is approximately 6 pmol/L); fasting reference intervals typically fall between about 2 and 25 µIU/mL depending on the assay and population.
- C-peptide: the 31-amino-acid connecting peptide, reported in ng/mL or nmol/L (1 ng/mL is approximately 0.33 nmol/L); fasting values commonly range from about 0.9 to 7.1 ng/mL (0.3 to 2.4 nmol/L).
- Proinsulin: the intact precursor; fasting concentrations are normally low (typically below 5 to 10 pmol/L) and rise disproportionately in insulinoma and beta-cell stress.
- Insulin/C-peptide molar ratio: a molar ratio above 1 during hypoglycemia is a hallmark of exogenous insulin exposure, whereas endogenous hyperinsulinism usually produces a ratio below 1.
Testing Samples
Serum
Serum is the most widely used matrix for insulin, C-peptide, and proinsulin immunoassays. Blood should be collected after an overnight fast of 8 to 12 hours where clinically indicated, allowed to clot, and centrifuged promptly, ideally within one hour, to minimize proteolytic degradation and hemolysis-related interference. For delayed analysis, aliquots should be stored frozen at −20 °C or below, preferably at −70 °C to −80 °C, with repeated freeze-thaw cycles avoided.
Plasma
Plasma collected with EDTA or heparin anticoagulation is acceptable on most automated immunoassay platforms, provided the laboratory has verified method performance for the specific matrix. Plasma permits immediate centrifugation and reduced ex vivo proteolysis compared with serum. Matrix-specific reference intervals should be established or verified, as serum and plasma results may differ slightly.
Urine
Because C-peptide is cleared renally while insulin undergoes extensive hepatic and peripheral degradation, urine is a useful matrix for C-peptide-based assessment. A 24-hour urine collection quantifies total endogenous secretion, while the spot urine C-peptide-to-creatinine ratio (UCPCR) offers a convenient, non-invasive index applied in diabetes classification and residual beta-cell function studies. Urine is also the primary matrix for anti-doping detection of insulin analogues by LC-MS/MS.
Testing Items
Endogenous insulin testing panels are constructed according to the clinical or regulatory question at hand. Core and specialized test items include the following:
- Fasting serum insulin and C-peptide as baseline measures of endogenous secretion
- Fasting proinsulin as a marker of beta-cell stress and insulinoma
- Insulin/C-peptide molar ratio for endogenous versus exogenous discrimination
- Supervised 72-hour fast biochemistry, including glucose, insulin, C-peptide, proinsulin, beta-hydroxybutyrate, and a sulfonylurea/secretagogue screen at the time of hypoglycemia
- Dynamic beta-cell function tests, such as the oral glucose tolerance test (OGTT), mixed-meal tolerance test (MMTT), and glucagon stimulation test with serial insulin and C-peptide sampling
- 24-hour urinary C-peptide and spot urine UCPCR
- Insulin autoantibodies and heterophilic antibody interference work-up
- Insulin analogue differentiation (for example, lispro, aspart, glargine, detemir, and degludec) by LC-MS/MS or immunoaffinity-electrophoretic methods
Testing Methods
Immunoassay Platforms (CLIA, ECLIA, ELISA, RIA)
Sandwich immunoassays are the workhorse of routine endogenous insulin and C-peptide measurement. Electrochemiluminescence immunoassay (ECLIA) and chemiluminescent immunoassay (CLIA) platforms on automated analyzers offer high precision, throughput, and functional sensitivity down to approximately 0.2 to 1 µIU/mL for insulin. Enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay (RIA) remain important in research settings; older RIAs exhibited cross-reactivity with proinsulin and some analogues, which must be considered when comparing historical data. Assay-specific cross-reactivity with insulin analogues varies considerably between platforms and must be documented by the performing laboratory.
Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS)
LC-MS/MS with immunoaffinity enrichment provides molecular specificity that immunoassays cannot match. It can separate and quantify endogenous human insulin, structurally distinct analogues, and their metabolites in a single run, achieving limits of detection in the low pg/mL range after enrichment. This technique underpins confirmatory analysis in anti-doping programs and is increasingly used in clinical toxicology to characterize surreptitious use of insulin analogues.
Electrophoretic and Immunoaffinity Techniques
Isoelectric focusing (IEF) combined with immunoblotting separates insulin species and analogues on the basis of charge differences and has historically served as a complementary screening technique in doping control. Immunoprecipitation and immunoaffinity enrichment steps are frequently coupled to mass spectrometry to concentrate low-abundance peptides from urine or plasma prior to confirmatory analysis.
Quality Assurance and Standardization
Accredited third-party laboratories performing endogenous insulin testing typically operate under ISO 15189 for medical laboratories or ISO/IEC 17025 for general testing laboratories. Key quality requirements include:
- Calibration traceability to WHO International Standards and Reference Reagents for insulin and C-peptide
- Documented cross-reactivity of insulin assays with proinsulin and each insulin analogue
- Verification of imprecision, bias, linearity, and detection capability, guided by recognized clinical laboratory standards documents
- Interference studies covering hemolysis, lipemia, bilirubin, biotin, heterophilic antibodies, and insulin autoantibodies
- Participation in external quality assessment or proficiency testing programs with peer-comparable reporting units
Applications
Differential Diagnosis of Hypoglycemia
Paired insulin and C-peptide measurement is central to distinguishing endogenous hyperinsulinism, such as insulinoma, beta-cell hyperplasia, or sulfonylurea exposure, from exogenous insulin administration. Widely applied criteria for endogenous hyperinsulinism during a supervised fast at plasma glucose below 3.0 mmol/L (55 mg/dL) include insulin of at least 18 pmol/L (3 µIU/mL), C-peptide of at least 0.2 nmol/L (0.6 ng/mL), proinsulin of at least 5 pmol/L, beta-hydroxybutyrate of 2.7 mmol/L or below, and a negative sulfonylurea screen. Suppressed C-peptide with elevated insulin confirms exogenous exposure, including factitious or malicious insulin administration.
Diabetes Classification and Beta-Cell Function Monitoring
Stimulated C-peptide responses to OGTT, MMTT, or glucagon, together with fasting C-peptide and UCPCR, are used to classify diabetes subtypes, to stage evolving type 1 diabetes, to guide decisions between insulin and non-insulin therapy, and to monitor residual beta-cell function in intervention trials and after islet or pancreas transplantation. Commonly applied thresholds indicating marked insulin deficiency include a fasting C-peptide below approximately 0.2 to 0.3 nmol/L or a stimulated C-peptide below approximately 0.5 to 0.8 nmol/L, although cut-offs are assay- and protocol-dependent.
Anti-Doping Surveillance
Insulin and its analogues are listed as prohibited substances in sport by the World Anti-Doping Agency, which publishes technical documents governing their detection. Analysis in accredited anti-doping laboratories centers on LC-MS/MS and IEF-immunoblot confirmation of analogues in urine at very low detection levels. Because recombinant human insulin is structurally identical to endogenous insulin, detection strategies for abuse focus on charge- or mass-distinguishable analogues together with corroborating pharmacokinetic evidence.
Pharmaceutical and Translational Research
C-peptide is the preferred endpoint for endogenous secretion in clinical trials of insulin products, beta-cell preservation therapies, and stem-cell-derived islet products, because co-administered analogues do not cross-react in validated C-peptide assays. Endogenous insulin testing also supports pharmacodynamic modeling, hyperinsulinemic-euglycemic clamp studies, and bioanalytical method validation under internationally harmonized guidelines for large-molecule assays.
FAQ
Why is C-peptide the preferred marker of endogenous insulin secretion?
C-peptide is secreted in equimolar proportion to insulin but has a longer half-life, negligible hepatic extraction, and no cross-reactivity with therapeutic insulin preparations. It therefore reflects endogenous beta-cell output even in patients receiving insulin therapy.
Can a laboratory distinguish endogenous insulin from injected insulin?
Yes. Injected insulin raises circulating insulin while suppressing C-peptide, producing an insulin/C-peptide molar ratio above 1, whereas endogenous hyperinsulinism elevates both. Structurally modified analogues can be individually identified by LC-MS/MS. Regular human insulin, being chemically identical to endogenous insulin, is instead inferred from the discordant insulin and C-peptide pattern.
What are the main pre-analytical requirements?
Overnight fasting collection where indicated, prompt centrifugation within about one hour, avoidance of hemolysis, refrigerated or frozen storage with minimal freeze-thaw cycles, and clear documentation of insulin therapy, secretagogue use, and renal function, all of which influence result interpretation.
What interferences affect endogenous insulin assays?
Insulin autoantibodies and heterophilic antibodies can bridge assay antibodies and generate spuriously high or low results, while hemolysis, lipemia, and high-dose biotin are additional recognized interferents on certain platforms. Suspicious results should be confirmed using an alternative platform, serial dilution linearity checks, or LC-MS/MS.
Which standards govern endogenous insulin testing?
Laboratory operations are typically accredited to ISO 15189 or ISO/IEC 17025, immunoassay calibration should be traceable to WHO International Standards, and anti-doping analysis follows the technical documents and laboratory standards published by the relevant international anti-doping authority. Accredited third-party laboratories integrate these requirements into their documented quality management systems.